##### 



Exhibit 10.6
  AMENDMENT #1  TO AMENDED AND RESTATED DEVELOPMENT,  LICENSE AND SUPPLY AGREEMENT
  ®
 ®
 ® ®




---



##### 








---



##### 



CIMA LABS INC.
    
    ALAMO PHARMACEUTICALS, LLCBY: /s/ R. K. Khankari
    
    BY:/s/ Samuel SimmonsNAME: R. K. Khankari
    
    NAME: Samuel SimmonsTITLE: V.P. Worldwide Drug Delivery, R&D
    
    TITLE: Chief Financial OfficerDATE: October 14, 2005
    
    DATE: October 19, 2005




---



##### 



Schedule B-l
 Details of Development Activities, Costs and Timing
 ***
    
 ***
    
    Portions of this page have been omitted
pursuant to a request for Confidential Treatment and filed separately with the
Commission.




---



##### 



Schedule B-l (Continued)
 ***
     ***
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    *****
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    *****
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    *****
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
  
 ***
    
    Portions of this page
have been omitted pursuant to a request for Confidential Treatment and filed
separately with the Commission.




---



##### 



Schedule B-l (Continued)
 ***
     
 ***
    
    Portions of this page have been omitted
pursuant to a request for Confidential Treatment and filed separately with the
Commission.




---



##### 



Schedule B-l (Continued)
 ***
     
 ***
    
    Portions of this page have been omitted
pursuant to a request for Confidential Treatment and filed separately with the
Commission.




---



##### 



Schedule B-l (Continued)
 ***
  ***
    
    ***
 *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    *****
    
    
    *
    **
    
    
    *
    **
    
    
    *
    *****
    
    
    
    
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    *****
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
 ***
   ***
    
    ***
    
    ***
   
 ***
    
    Portions of this page have been omitted
pursuant to a request for Confidential Treatment and filed separately with the
Commission.




---



##### 



Schedule B-l (Continued)
 ***
     ***
    
    ***
 *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    *****
    
    
    *
    **
    
    
    *
    *****
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    *****
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
    
    
    *
    **
   
 ***
    
    Portions of this page have been omitted
pursuant to a request for Confidential Treatment and filed separately with the
Commission.




---



##### 



Schedule B-l (Continued)
 ***
  
 
 ***
    
    Portions of this page have been omitted
pursuant to a request for Confidential Treatment and filed separately with the
Commission.




---



##### 



Clozapine DuraSolv®
 Anticipated Product Attributes:
 ***
    
 ***
    
    Portions of this page have been omitted
pursuant to a request for Confidential Treatment and filed separately with the
Commission.